10 tuloksia
BACKGROUND OF THE INVENTION
This invention is related to a diagnostic assay useful for determining which individuals afflicted with gross cystic disease of the breast will develop breast cancer.
Approximately 200,000 women develop breast cancer each year. It is the leading cause of death of women
BACKGROUND OF THE INVENTION
Type 2 diabetes, also referred to as non-insulin dependent diabetes mellitus (NIDDM), afflicts between 80 and 90% of all diabetic patients in developed countries. In the United States alone, approximately 15 million people, and more than 100 million worldwide, are
The present invention relates to compositions containing select combinations of gamma linolenic acid (GLA), iodine, and preferably selenium, for improving breast health in women.
BACKGROUND OF THE INVENTION
Among the most common health issues affecting women today is that of breast health, most
TECHNICAL FIELD
This invention pertains to a method to inhibit angiogenesis in cancerous and non-cancerous diseases by use of Noni juice and its active extracts.
BACKGROUND ART
Angiogenesis
In an adult, two types of blood vessels can potentially be found. The normal blood vessel is a resting,
TECHNICAL FIELD
This invention pertains to a method to inhibit angiogenesis in cancerous and non-cancerous diseases by use of Noni juice and its active extracts.
BACKGROUND ART
Angiogenesis
In an adult, two types of blood vessels can potentially be found. The normal blood vessel is a resting,
BACKGROUND OF THE INVENTION
Type 2 diabetes, also referred to as non-insulin dependent diabetes mellitus (NIDDM), afflicts between 80 and 90% of all diabetic patients in developed countries. In the United States alone, approximately 15 million people, and more than 100 million worldwide, are
BACKGROUND OF THE INVENTION
Type 2 diabetes, also referred to as non-insulin dependent diabetes mellitus (NIDDM), afflicts between 80 and 90% of all diabetic patients in developed countries. In the United States alone, approximately 15 million people, and more than 100 million worldwide, are
BACKGROUND OF THE INVENTION
Type 2 diabetes, also referred to as non-insulin dependent diabetes mellitus (NIDDM), afflicts between 80 and 90% of all diabetic patients in developed countries. In the United States alone, approximately 15 million people, and more than 100 million worldwide, are
BACKGROUND OF THE INVENTION
Type 2 diabetes, also referred to as non-insulin dependent diabetes mellitus (NIDDM), afflicts between 80 and 90% of all diabetic patients in developed countries. In the United States alone, approximately 15 million people, and more than 100 million worldwide, are
CROSS REFERENCE TO RELATED APPLICATIONS
This application is filed under the provisions of 35 U.S.C. .sctn.371 of International Application PCT/KR02100894 filed May 14, 2002, claiming priority to KR2001-27943 filed May 22, 2001.
TECHNICAL FIELD
The present invention relates to a lectin protein